[Effectiveness of biomarker determination (TIMP 2*IGFBP 7) early detection of acute kidney injury in acute patients]

Rodríguez-Rojas L, García-Carpintero EE
Record ID 32018016169
Spanish
Original Title: Efectividad de la determinación de biomarcadores (TIMP 2*IGFBP 7) para la detección precoz de insuficiencia renal aguda en pacientes agudos
Authors' objectives: To evaluate the diagnostic effectiveness and clinical utility of urinary TIMP-2*IGFBP-7 measurement for the early detection of AKI in acutely ill patients, and to assess its economic, ethical, legal, organizational, and social implications.
Authors' results and conclusions: Twenty-five prospective cohort studies evaluating the diagnostic performance of the biomarker were identified. The meta-analysis showed a pooled sensitivity of 64% and specificity of 71%, with a diagnostic odds ratio of 4.39, indicating limited diagnostic performance. Considerable heterogeneity was observed across studies. In patients with more severe AKI (KDIGO stages 2–3), sensitivity increased to 71% and specificity was 65%. Among ICU patients, sensitivity and specificity were 81% and 51%, whereas in cardiovascular surgery patients they were 54% and 73%, respectively. Evidence regarding clinical utility was limited. Only one of three randomized clinical trials evaluating biomarker-guided treatment strategies, conducted in patients after cardiovascular surgery, demonstrated a reduction in AKI incidence through the implementation of nephroprotective measures. The other two trials were stopped early because of futility. Economic evaluations suggested that NEPHROCHECK® may be cost-effective in specific patient populations, particularly those admitted to the ICU, and may save healthcare costs. Conclusions: Overall, the available evidence indicates that the test has moderate diagnostic accuracy and a potentially limited clinical benefit, mainly in patients undergoing cardiovascular surgery.
Authors' methods: A systematic review of the scientific literature was conducted, including systematic reviews and original studies. Methodological quality and certainty of evidence were assessed using validated tools.
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://hdl.handle.net/20.500.12105/27797
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Acute Kidney Injury
  • Biomarkers
  • Critical Care
  • Rapid Diagnostic Tests
  • Kidney Function Tests
Keywords
  • acute kidney injury
  • biomarkers
  • TIMP-2*IGFBP-7
Contact
Organisation Name: Agencia de Evaluacion de Tecnologias Sanitarias
Contact Address: Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;
Contact Name: Esther E. García Carpintero
Contact Email: eegarcia@isciii.es
Copyright: Agencia de Evaluacion de Tecnologias Sanitarias
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.